Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 227-228

  Krug, L M ^a   Miller, V A ^a   Kalemkerian, G P ^b   Kraut, M J ^b   Ng, K K ^a   Heelan, R T ^a   Pizzo, B A ^a   Perez, W ^a   McClean, N ^a   Kris, M G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Dolastatin 10; Non small cell lung cancer

Indexed keywords

DOLASTATIN 10;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGOPEPTIDES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034093431     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008349209956     Document Type: Article

References (8)